CN1989122B - 新型环戊[b]苯并呋喃衍生物及其用途 - Google Patents

新型环戊[b]苯并呋喃衍生物及其用途 Download PDF

Info

Publication number
CN1989122B
CN1989122B CN2005800241153A CN200580024115A CN1989122B CN 1989122 B CN1989122 B CN 1989122B CN 2005800241153 A CN2005800241153 A CN 2005800241153A CN 200580024115 A CN200580024115 A CN 200580024115A CN 1989122 B CN1989122 B CN 1989122B
Authority
CN
China
Prior art keywords
group
hydrogen
amino
alkylamino
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800241153A
Other languages
English (en)
Chinese (zh)
Other versions
CN1989122A (zh
Inventor
N·迪德里希斯
T·法里希
I·格尔拉赫
J·拉戈持
J·舒马赫
K·特德
E·霍尔瓦特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Intermed Discovery GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermed Discovery GmbH filed Critical Intermed Discovery GmbH
Publication of CN1989122A publication Critical patent/CN1989122A/zh
Application granted granted Critical
Publication of CN1989122B publication Critical patent/CN1989122B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
CN2005800241153A 2004-05-18 2005-05-14 新型环戊[b]苯并呋喃衍生物及其用途 Expired - Fee Related CN1989122B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004024504.5 2004-05-18
DE102004024504A DE102004024504A1 (de) 2004-05-18 2004-05-18 Neue Cylopenta[b]benzofuran-Derivate und ihre Verwendung
PCT/EP2005/005298 WO2005113529A2 (de) 2004-05-18 2005-05-14 Neue cylopenta[b]benzofuran-derivate und ihre verwendung

Publications (2)

Publication Number Publication Date
CN1989122A CN1989122A (zh) 2007-06-27
CN1989122B true CN1989122B (zh) 2013-07-24

Family

ID=35207782

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800241153A Expired - Fee Related CN1989122B (zh) 2004-05-18 2005-05-14 新型环戊[b]苯并呋喃衍生物及其用途

Country Status (14)

Country Link
US (1) US8030347B2 (https=)
EP (1) EP1751127B1 (https=)
JP (1) JP2007538031A (https=)
KR (1) KR101215164B1 (https=)
CN (1) CN1989122B (https=)
AU (1) AU2005245104B2 (https=)
BR (1) BRPI0510403A (https=)
CA (1) CA2567404C (https=)
DE (1) DE102004024504A1 (https=)
IL (1) IL179257A (https=)
MX (1) MXPA06013182A (https=)
RU (1) RU2415847C9 (https=)
WO (1) WO2005113529A2 (https=)
ZA (1) ZA200609444B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1771169A1 (en) 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Methods for treating hepatitis c
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1693059A1 (en) * 2005-02-22 2006-08-23 Deutsches Krebsforschungszentrum Use of rocaglamide derivatives as NF-AT-specific inhibitors for the treatment of certain inflammatory diseases
EP2189453A1 (en) * 2008-11-25 2010-05-26 Université Louis Pasteur Rocaglaol derivatives as cardioprotectant agents
EP2457907A1 (en) * 2010-11-16 2012-05-30 Université de Strasbourg Flavagline derivatives as neuroprotective agents
US20140255432A1 (en) * 2011-07-27 2014-09-11 Ohio State Innovation Foundation Silvestrol, silvestrol analogs and uses thereof
FR3023290B1 (fr) * 2014-07-04 2016-08-19 Pf Medicament Derives de flavaglines
EP3888658B1 (en) 2015-11-25 2023-12-27 Effector Therapeutics, Inc. Eif4-a-inhibiting compounds and methods related thereto
EP3755693B1 (en) 2018-02-19 2024-06-12 Memorial Sloan-Kettering Cancer Center Agents and methods for treating dysproliferative diseases
EP3639820A1 (en) 2018-10-16 2020-04-22 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Flavagline derivatives for inhibition of kras oncogene activation
CN110646616B (zh) * 2019-09-05 2023-05-30 桂林理工大学 一种检测血清中人cTnI的超敏荧光猝灭免疫传感器及检测方法
CN110776486B (zh) * 2019-10-23 2022-05-20 中国药科大学 一种苯并呋喃类小分子p2y14受体抑制剂，及其制备和应用
CA3230542A1 (en) 2021-09-01 2023-03-09 Krishnaraj Rajalingam Novel ras inhibitors
CN116077483A (zh) * 2021-11-05 2023-05-09 上海中医药大学 楝酰胺及其类似物的药物用途
CN115385924B (zh) * 2022-10-06 2023-10-13 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一种具有抗肿瘤活性的环戊烷苯并呋喃类化合物及其应用
WO2024175662A1 (en) 2023-02-23 2024-08-29 KHR Biotec GmbH Flavagline derivatives as ras inhibitors
JP2026508161A (ja) 2023-02-23 2026-03-10 エスジェーピー バイオテック ゲーエムベーハー 新規ＲＡＳ阻害剤３ａＨ－シクロペンタ［ｂ］ベンゾフラン－３ａ－イル
WO2025092976A1 (zh) * 2023-11-03 2025-05-08 映恩生物制药（苏州）有限公司 蛋白翻译抑制剂
TW202545938A (zh) * 2024-01-16 2025-12-01 大陸商映恩生物製藥（蘇州）有限公司 一種蛋白轉譯抑制劑的偶聯物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420393B1 (en) * 1998-08-05 2002-07-16 Bayer Aktiengesellschaft Cyclopentabenzofuran derivatives and their use
US6518274B1 (en) * 1998-08-05 2003-02-11 Bayer Aktiengesellschaft Use of cyclopentabenzofuran-derivatives for combating (NF-κB)-dependent diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU191264B (en) * 1984-01-13 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for production of derivatives of 7-oxo-prostacyclin with selective biological effect
KR100381584B1 (ko) * 1994-07-22 2003-08-21 알타나 파마 아게 디히드로벤조푸란
DE19934952A1 (de) * 1998-07-30 2000-02-03 Novartis Ag Cyclopentabenzofuran-Derivate
DE10158561A1 (de) * 2001-11-29 2003-06-12 Bayer Ag Neue Verwendung von Cyclopentabenzofuranen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420393B1 (en) * 1998-08-05 2002-07-16 Bayer Aktiengesellschaft Cyclopentabenzofuran derivatives and their use
US6518274B1 (en) * 1998-08-05 2003-02-11 Bayer Aktiengesellschaft Use of cyclopentabenzofuran-derivatives for combating (NF-κB)-dependent diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Nicole Diedrichs,et al,.A Highly Efficient Synthesis of Rocaglaols by a Novel α-Arylation of Ketones,.Eur. J. Org. Chem.9.2005,91731-1735. *
说明书第21栏实施例I-6、第22栏实施例I-7、第1栏第47行至第2栏第48行、权利要求1.

Also Published As

Publication number Publication date
AU2005245104A1 (en) 2005-12-01
DE102004024504A1 (de) 2006-02-16
ZA200609444B (en) 2008-01-30
RU2006144710A (ru) 2008-06-27
JP2007538031A (ja) 2007-12-27
IL179257A0 (en) 2007-03-08
RU2415847C2 (ru) 2011-04-10
EP1751127B1 (de) 2012-07-11
US20090018113A1 (en) 2009-01-15
EP1751127A2 (de) 2007-02-14
WO2005113529A2 (de) 2005-12-01
KR20070011522A (ko) 2007-01-24
WO2005113529A3 (de) 2006-02-09
US8030347B2 (en) 2011-10-04
KR101215164B1 (ko) 2012-12-24
CA2567404C (en) 2014-04-01
IL179257A (en) 2013-02-28
AU2005245104B2 (en) 2011-07-28
CA2567404A1 (en) 2005-12-01
RU2415847C9 (ru) 2011-08-10
BRPI0510403A (pt) 2007-10-23
MXPA06013182A (es) 2007-02-14
CN1989122A (zh) 2007-06-27

Similar Documents

Publication Publication Date Title
CN1989122B (zh) 新型环戊[b]苯并呋喃衍生物及其用途
CN111051295B (zh) 杂环化合物及其用途
CN117980298A (zh) 作为kif18a抑制剂的化合物
TWI331034B (en) Inhibitors of cyclin-dependent kinases and their use
WO2021043322A1 (zh) 氮杂环庚烷并嘧啶类衍生物及其医药用途
WO2023280182A1 (zh) 作为kat6抑制剂的化合物
WO2019057123A1 (zh) 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物
CN102816124A (zh) 作为akt蛋白激酶抑制剂的羟基化和甲氧基化的环戊二烯并[d]嘧啶
CN103038218B (zh) 稠环吡啶化合物
CN109071548A (zh) 可用于治疗尤其是癌症的吡咯并咪唑衍生物或其类似物
CN110407854B (zh) 新的四环化合物
JP4933428B2 (ja) ピロロベンズイミダゾロン及びその抗増殖薬としての使用
WO2001083452A1 (en) Novel tricyclic compounds
CN110407839B (zh) 含杂芳基酰胺结构的三唑并杂环类化合物的制备及应用
WO1999061414A1 (en) Novel substituted guanidine derivatives and process for producing the same
HK1108885A (en) Novel cylopenta[b]benzofuran derivatives and the utilization thereof
NZ549330A (en) 2H or 3H-benzo[e]indazol-1-yl carbamate derivatives, the preparation and therapeutic use thereof
WO2024067676A1 (zh) 作为sumo活化酶抑制剂的化合物
HK40051268A (en) A heterocyclic compound, preparation method therefor, and use
WO2023158221A1 (ko) 프로스타글란딘 e2 수용체에 대한 저해 활성을 갖는 신규 화합물 및 항암제를 포함하는 암 치료용 약학 조성물
CN113264925A (zh) 一种杂环化合物及其制备方法和用途
CN121057736A (zh) 大环杂环化合物及其用途
CN104245698A (zh) 含氮杂环化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: INTEC MED EXPLORE LIMITED LIABILITY COMPANY

Free format text: FORMER OWNER: BAYER HEALTHCARE AG

Effective date: 20070824

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20070824

Address after: Borussia Dortmund

Applicant after: Bayer Healthcare AG

Address before: Germany Leverkusen

Applicant before: Bayer Healthcare AG

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1108885

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1108885

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130724

Termination date: 20140514